Concepedia

Implications for sequencing of biologic therapy and choice of second <scp>anti‐TNF</scp> in patients with inflammatory bowel disease: results from the <scp>IMmunogenicity</scp> to Second <scp>Anti‐TNF</scp> therapy (<scp>IMSAT</scp>) therapeutic drug monitoring study

Neil Chanchlani, Simeng Lin, Marcus Auth, Chai Leng Lee, Helena Robbins, Shi Jie Looi, Senthil Murugesan, Tom Riley, Cathryn Preston, Sophie Stephenson,

Alimentary Pharmacology & Therapeutics · 2022 · 17 citations · 24 references

DOIFull text

Open access

Abstract

Irrespective of drug sequence, immunogenicity to the first anti-TNF agent was associated with immunogenicity to the second, which was mitigated by the introduction of an immunomodulator in patients with immunogenic, but not pharmacodynamic treatment failure.

References

24

The REDCap consortium: Building an international community of software platform partners

Paul A. Harris, Robert J. Taylor, Brenda L. Minor et al. · Journal of Biomedical Informatics · 2019 · 22.2K citations · Full text

, , +13

Index for rating diagnostic tests

W. J. Youden · Cancer · 1950 · 11.1K citations · Full text

, , +6

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch et al. · New England Journal of Medicine · 2010 · 3.1K citations · Full text

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology · 2015 · 859 citations

, , +5

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Nicholas A. Kennedy, Graham Heap, Harry Green et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 655 citations · Full text

, , +9